ReviewJournal of molecular medicine (Berlin, Germany)2004
Therapeutics for Duchenne muscular dystrophy: current approaches and future directions.
Review in Journal of molecular medicine (Berlin, Germany), 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 138 citations in OpenAlex.
- Biomarkers for Duchenne muscular dystrophy progression: impact of age in the mdx tongue spared muscle.Skeletal muscle · 2023Article
- Biomarkers for Duchenne muscular dystrophy progression: impact of age in the mdx tongue spared muscle.Research square · 2023Article
- Identifying FDA-Approved Drugs that Upregulate Utrophin A as a Therapeutic Strategy for Duchenne Muscular Dystrophy.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Early administration of L-arginine inFASEB bioAdvances · 2021Article
- Ixazomib, an oral proteasome inhibitor, exhibits potential effect in dystrophin-deficient mdx mice.International journal of experimental pathology · 2021Article
- Second-generation compound for the modulation of utrophin in the therapy of DMD.Human molecular genetics · 2015Article
- Effectiveness of diffusion tensor imaging in assessing disease severity in Duchenne muscular dystrophy: preliminary study.Pediatric radiology · 2015Article
- An image processing approach to analyze morphological features of microscopic images of muscle fibers.Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society · 2014Article
- Muscle-specific SIRT1 gain-of-function increases slow-twitch fibers and ameliorates pathophysiology in a mouse model of duchenne muscular dystrophy.PLoS genetics · 2014Article
- Post-natal induction of PGC-1α protects against severe muscle dystrophy independently of utrophin.Skeletal muscle · 2014Article
- Participation in daily life activities and its relationship to strength and functional measures in boys with Duchenne muscular dystrophy.Disability and rehabilitation · 2014Article
- The different impact of a high fat diet on dystrophic mdx and control C57Bl/10 mice.PLoS currents · 2011Article
- Article
- Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy.The American journal of pathology · 2011Article
- Dystrophins, utrophins, and associated scaffolding complexes: role in mammalian brain and implications for therapeutic strategies.Journal of biomedicine & biotechnology · 2010Review
- Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Tracking dynamics of muscle engraftment in small animals by in vivo fluorescent imaging.Journal of visualized experiments : JoVE · 2009Article
- miRNAS in normal and diseased skeletal muscle.Journal of cellular and molecular medicine · 2009Review
- A novel functional assessment of the differentiation of micropatterned muscle cells.Journal of biomechanics · 2008Article
- PGC-1 coactivators and skeletal muscle adaptations in health and disease.Current opinion in genetics & development · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Duchenne muscular dystrophy (DMD) is the most common X-linked neuromuscular disorder. The devastating nature of DMD has led to an intense effort toward finding a cure for this disease, dating back to the time when Duchenne first initiated clinical trials using faradic stimulation for DMD patients. Unfortunately despite the passage of some 150 years the disease remains incurable, and its medical management is largely supportive. However, the discovery of the DMD gene about 20 years ago has allowed a change in the focus of therapeutic strategy dramatically toward delivery of the missing gene/protein. Indeed, some degree of success has been achieved in preclinical animal studies using such strategies, and gene therapy trials are currently underway in humans. Pharmacological approaches for DMD are also being developed since they can circumvent some of the technical problems associated with gene and cell based therapy. This review explores developments in therapeutic approaches for DMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.